What is Breo Ellipta?
Breo Ellipta is a breath of fresh air in treating asthma.1 This revolutionary treatment is specifically designed to deliver 24 hours of easier breathing out of only a single inhalation. How can it get its name? ‘Breo’ identifies the actual medicines and ‘Ellipta’ is the easy to use inhalation apparatus. Both of these molecules work together to control your asthma:3 fluticasone furoate helps decrease inflammation in the lungs. Inflammation in the lungs may result in breathing problems. Vilanterol opens lung airways by helping the muscles around them stay relaxed, preventing symptoms. The blend of these molecules generates the creation — breathing easier round the clock at a single inhalation.
How can it help your asthma?
Breo Ellipta is used to prevent and control symptoms of asthma, such as wheezing. It is the first and only once-daily inhaled asthma combination remedy which helps patients breathe better by improving lung function for a full 24 hours.Breo Ellipta isn’t utilized to relieve sudden breathing problems and will not substitute a rescue inhaler, such as Ventolin. Once-daily Breo Ellipta treats two of the main causes of asthma symptoms — airway constriction and airway inflammation.
Can Breo Asthma Ellipta help control asthma symptoms?
Not only can once-daily Breo Ellipta help control asthma symptoms, it can prevent them from occurring in the first location. Breo Ellipta was demonstrated to boost symptom-free times compared with an inhaled corticosteroid alone. It is well worth noting that Breo Ellipta is not a rescue medication though. It should not be used to treat sudden breathing Issues
Asthma patients treated with Breo Ellipta (also known as Relvar Ellipta) had greater improvement in asthma control in comparison to usual care, according to results from the Salford Lung Study (SLS) reported by GlaxoSmithKline and Innoviva Inc..
Included in the Stage 3, open-label, randomized study, over 4,000 asthma sufferers were treated either with Breo Ellipta 100/25mcg or 200/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) or standard care, which included ICS administered as monotherapy or as ICS/LABA combinations. In the usual care arm, 36 percent of patients were on an ICS alone, also 64% were on an ICS/LABA mix at the time of initiating research medication.
For the Key effectiveness analysis, at 24 months a significantly higher percent of individuals with uncontrolled asthma and initiated on therapy with FF/VI attained better control of their asthma (71%) Measured from the Asthma Control Test (ACT), in comparison with patients ongoing usual care treatment (56%). Improvement was defined as an ACT complete score ≥20 or an increase from baseline of ≥3. Statistically significant findings were also found at 12, 40 and 52 weeks.
“Despite medical advances, more than half of individuals with asthma continue to experience poor control and significant symptoms. The main endpoint of this study showed that patients initiated with [Breo Ellipta] treatment had twice the odds of achieving an improvement in asthma control compared with patients continuing usual care in this study in everyday clinical practice,” explained Eric Dube, senior vice president and mind, Global Respiratory Franchise, GSK. “This study has been a tremendous partnership effort involving healthcare professionals, patients, academics and GSK and we would like to thank everyone who has helped to produce this unique study potential.”